Reactivation of FOXO3A or suppression of FOXM1 in cancer cells reduces DNA repair capacity and cell survival rates while augmenting cell death and enhancing the efficacy of DNA-damaging anticancer therapies [57,58]. Here, FOXM1 is linked to cancer.